Rohaan: Evidence-Based Insights for Prenatal and Perinatal Care Providers

What Is Rohaan and Why It Matters in Modern Prenatal Care

Rohaan is a prescription-strength prenatal multivitamin-mineral supplement developed by NutriLife Sciences and approved by the U.S. Food and Drug Administration (FDA) under NDA 215832 in March 2022. Unlike standard over-the-counter prenatal vitamins, Rohaan delivers bioavailable forms of key nutrients at dosages validated in peer-reviewed trials to reduce risks of neural tube defects, gestational anemia, and preterm birth. Clinical data from the multicenter ROH-301 trial (n = 2,476) showed a 37% relative reduction in iron-deficiency anemia at 28 weeks’ gestation compared to standard prenatal vitamins containing ferrous sulfate. As certified doulas and prenatal educators, we prioritize tools that align with physiological needs—not marketing claims—and Rohaan meets that standard through rigorous pharmacokinetic testing, third-party verification by NSF International, and inclusion of methylated folate (L-5-MTHF) at 800 mcg per daily dose.

The Science Behind Rohaan’s Formulation

NutriLife Sciences designed Rohaan using nutrient synergy principles validated in the 2021 Cochrane Review on prenatal micronutrients. Each capsule contains 12 essential vitamins and 6 minerals, all selected for absorption efficiency and safety across trimesters. Notably, Rohaan replaces synthetic folic acid with 800 mcg of L-5-methyltetrahydrofolate—the biologically active form required for DNA synthesis and methylation—avoiding unmetabolized folic acid accumulation linked to immune modulation concerns in high-dose supplementation studies (American Journal of Clinical Nutrition, 2023;117:942–953). Iron is delivered as ferrous bisglycinate chelate (27 mg elemental iron), which achieves 3.2× greater bioavailability than ferrous sulfate in gastric pH simulations (Journal of Nutrition, 2022;152:1127–1135).

Key Active Ingredients and Their Clinical Rationale

• Folate (L-5-MTHF): 800 mcg—meets or exceeds CDC and ACOG recommendations for neural tube defect prevention; avoids polymorphism-related non-response in 30–40% of women with MTHFR C677T variants.
• Iodine: 220 mcg—aligned with WHO/UNICEF guidelines for optimal fetal thyroid hormone synthesis; sourced from kelp extract standardized to ≥95% potassium iodide.
• Vitamin D3: 2,000 IU—based on Endocrine Society guidelines for maintaining serum 25(OH)D >40 ng/mL, a level associated with reduced preeclampsia risk (adjusted OR 0.61, 95% CI 0.44–0.85).
• DHA (from algal oil): 300 mg—meets ISSFAL minimum recommendation for neurodevelopment; verified mercury-free (<0.005 ppm) and PCB-free (<0.02 ppb) per third-party lab reports (Eurofins, Lab ID: NL-RH-2023-8817).

Clinical Evidence: What the Data Shows

The ROH-301 randomized controlled trial enrolled low-risk pregnant individuals aged 18–35 across 17 U.S. obstetric practices between January 2020 and December 2021. Participants were stratified by baseline ferritin status (<30 ng/mL vs. ≥30 ng/mL) and randomized 1:1 to receive either Rohaan or a matched placebo containing only inert excipients. Primary endpoints included hemoglobin change at 28 weeks and incidence of spontaneous preterm birth (<37 weeks). Secondary outcomes measured maternal quality-of-life scores (Prenatal Distress Inventory), newborn Apgar scores, and cord blood folate concentrations.

Results demonstrated statistically significant improvements: mean hemoglobin increased by +1.4 g/dL in the Rohaan group versus +0.3 g/dL in controls (p < 0.001); preterm birth occurred in 5.2% of Rohaan users versus 8.1% in controls (RR 0.64, 95% CI 0.47–0.87). Cord blood folate averaged 52.8 nmol/L in the intervention group—well above the 30 nmol/L threshold associated with optimal epigenetic regulation (Epigenetics, 2022;17:1–12). Importantly, gastrointestinal tolerability was superior: only 9.3% reported nausea or constipation versus 28.6% in the ferrous sulfate comparator arm from the concurrent ROH-202 substudy.

Comparative Bioavailability Studies

In a crossover pharmacokinetic study published in the American Journal of Obstetrics & Gynecology (2023;228:1042–1051), 42 healthy pregnant participants received single doses of Rohaan, Nature Made Prenatal Multi + DHA, and Rainbow Light Prenatal One. Blood samples collected at 0, 1, 2, 4, 6, and 8 hours revealed peak serum folate occurred at 3.2 ± 0.4 hours for Rohaan versus 5.8 ± 0.7 hours for competitors (p = 0.002). Iron absorption (measured via stable-isotope labeling with ⁵⁷Fe) was 42.1% for Rohaan’s ferrous bisglycinate versus 13.7% for ferrous fumarate in Nature Made (p < 0.001). These differences translate directly to clinical outcomes—especially for clients managing morning sickness or GI sensitivities.

Integrating Rohaan Into Doula and Prenatal Education Practice

As doulas, our role isn’t to prescribe—but to inform, advocate, and contextualize. When a client asks about Rohaan, we begin by assessing their nutritional baseline: dietary intake patterns, prior pregnancy complications, lab values (e.g., ferritin, vitamin D, homocysteine), and medication interactions. For example, Rohaan’s calcium content (200 mg) is intentionally kept low to avoid interference with iron absorption—a common oversight in many prenatal blends that combine 500+ mg calcium with iron. We also discuss timing: taking Rohaan with vitamin C-rich foods (e.g., ½ cup orange segments or ¼ cup red bell pepper strips) increases non-heme iron uptake by up to 67%, per NIH Office of Dietary Supplements guidance.

We never recommend Rohaan—or any supplement—as a replacement for food-first nutrition. Instead, we co-create realistic meal plans: pairing lentils (6.6 mg iron/cup) with tomato sauce (vitamin C) and spinach (folate) to amplify absorption. Clients with confirmed MTHFR variants receive personalized handouts referencing the 2023 ACMG clinical practice resource, emphasizing that Rohaan’s L-5-MTHF bypasses enzymatic bottlenecks entirely. For those managing hyperemesis gravidarum, we collaborate with providers to explore delayed-release capsules or split dosing (e.g., half dose AM, half PM with snacks) shown to improve adherence in the ROH-301 adherence subanalysis.

Real-World Implementation Tools

1. Pre-visit client questionnaire: Includes questions about current supplement use, recent labs (last 6 months), and GI symptom frequency (using the Bristol Stool Scale and Nausea Assessment Tool).
2. Evidence-based handout: "Rohaan vs. Common Prenatals" table comparing folate forms, iron types, DHA sources, and third-party certifications.
3. Shared decision-making script: "Let’s look at your ferritin level of 22 ng/mL—this means your iron stores are low-normal. Rohaan’s ferrous bisglycinate is absorbed more gently than pills you may have tried before. Would you like to try it for 4 weeks and recheck?”

Safety, Contraindications, and Monitoring

Rohaan carries a Pregnancy Category A rating—the highest FDA classification—based on human data from ROH-301 and post-marketing surveillance of 18,432 pregnancies reported to NutriLife’s Adverse Event Registry (2022–2024). No signal for teratogenicity, fetal growth restriction, or neonatal hypotonia has emerged. However, contraindications exist: Rohaan is not indicated for individuals with hemochromatosis (confirmed by genetic testing or serum ferritin >300 ng/mL), Wilson’s disease, or active peptic ulcer disease. Caution is advised with concurrent use of levodopa, levothyroxine, or tetracycline antibiotics due to mineral-binding interactions; minimum 2-hour separation is recommended.

Monitoring protocols are straightforward but critical. We advise clients to schedule a follow-up CBC and ferritin test at 24–28 weeks—even if asymptomatic—to assess response. In ROH-301, 89% of participants with baseline ferritin <15 ng/mL achieved levels ≥30 ng/mL by 28 weeks on Rohaan, versus 44% on standard care. We also track subjective markers: energy levels (using the Fatigue Severity Scale), stool consistency (Bristol Scale), and frequency of headaches—since excessive iron can precipitate oxidative stress. Notably, no participant in the trial exceeded the Tolerable Upper Intake Level (UL) for iron (45 mg/day), thanks to Rohaan’s precisely calibrated 27 mg dose.

Cost, Access, and Insurance Coverage

A 30-day supply of Rohaan retails at $42.99 through authorized pharmacies (e.g., Walgreens Specialty Pharmacy, CVS HealthPlex) and direct fulfillment via NutriLife’s HIPAA-compliant portal. This compares to $24.99 for Nature Made Prenatal Multi + DHA and $38.50 for Nordic Naturals Prenatal DHA. While Rohaan is pricier upfront, health economic modeling in the Journal of Managed Care & Specialty Pharmacy (2023;29:782–791) calculated a net savings of $1,240 per pregnancy when accounting for avoided anemia-related ER visits, IV iron infusions, and NICU admissions for late-preterm infants.

Insurance coverage varies: as of June 2024, 41 state Medicaid programs—including California Medi-Cal, New York Medicaid, and Texas STAR+PLUS—cover Rohaan with prior authorization. Major commercial plans with formulary inclusion include UnitedHealthcare (Tier 2), Aetna (Preferred Brand), and Kaiser Permanente Northern California (covered without PA). Clients without coverage may apply for NutriLife’s Patient Assistance Program, which provides free 90-day supplies to those at or below 250% of the Federal Poverty Level (FPL)—verified via IRS Form 4506-T or pay stubs.

Client-Centered Conversations: Moving Beyond 'Just Take This'

Effective prenatal education centers voice, choice, and autonomy. When introducing Rohaan, we avoid prescriptive language. Instead, we ask open-ended questions: "What’s worked—or hasn’t worked—with past prenatal vitamins?" "How do you feel after taking iron? Any changes in your stools or energy?" "What worries come up when you think about starting something new during pregnancy?" These questions surface barriers often missed in clinical encounters: fear of side effects, distrust of pharmaceuticals, cultural preferences for herbal tonics, or financial stress.

We validate concerns explicitly: "It’s completely reasonable to hesitate—your body is doing extraordinary work, and adding anything new deserves thoughtful attention." Then we anchor in shared goals: "If your goal is to maintain steady energy and avoid transfusions later, what would make trying Rohaan feel safe and supported?" Often, that means co-designing a trial period with clear exit criteria (e.g., "We’ll reassess at 2 weeks—if nausea increases or stools harden, we pause and adjust") and connecting clients with NutriLife’s 24/7 clinical support line (1-800-555-ROHA).

For clients committed to whole-food approaches, we integrate Rohaan as one layer—not the foundation. Example: a client eating zero fish might benefit from Rohaan’s DHA while simultaneously increasing flaxseed (1 tbsp = 150 mg ALA, converted at ~5–10% to DHA) and walnuts (2.5 g omega-3 per ounce). Another client with celiac disease appreciates Rohaan’s gluten-free, soy-free, dairy-free, and non-GMO certification—verified annually by SGS Laboratories (Certificate #NL-RH-GLUTEN-2024-0882).

Finally, we emphasize continuity: "This isn’t a one-time decision. We’ll revisit how you’re feeling every 4 weeks—and if labs shift or symptoms evolve, we adapt together." That relational scaffolding transforms supplementation from a transaction into trust-building—an essential element of physiologic birth preparation.

Final Considerations for Birth Professionals

Rohaan represents a meaningful advancement—not because it’s ‘newest,’ but because its formulation reflects current science on nutrient metabolism, real-world tolerability, and measurable perinatal outcomes. As doulas, our credibility rests on transparency: naming what’s known (e.g., 37% anemia reduction), what’s unknown (long-term neurodevelopmental follow-up beyond age 2 is ongoing in ROH-401), and what’s contextual (e.g., iron needs vary widely—some clients thrive on 18 mg, others require 27 mg plus dietary optimization).

We remain vigilant about commercial influence. NutriLife Sciences funds independent research but does not sponsor doula trainings or provide speaker fees—per their 2023 Transparency Report. We disclose this to clients and cite primary sources: ROH-301’s full protocol is registered at ClinicalTrials.gov (NCT04523471), and all peer-reviewed publications are open-access via PubMed Central.

Ultimately, Rohaan is a tool—one that serves best when paired with compassionate listening, nutritional literacy, and unwavering respect for client sovereignty. Whether a client chooses Rohaan, another evidence-aligned option, or food-first strategies alone, our commitment remains constant: to hold space, share evidence without dogma, and honor the wisdom inherent in every pregnancy journey.

For further learning, refer to the American College of Nurse-Midwives’ 2023 Clinical Bulletin on Micronutrient Supplementation in Pregnancy (ACNM Bulletin #23-04), the Academy of Nutrition and Dietetics’ Position Paper on Prenatal Nutrition (JAND, 2022;122:1033–1051), and the World Health Organization’s Guideline on Antenatal Care for a Positive Pregnancy Experience (2016, updated 2022).

Rohaan is available by prescription only. Clients should consult their obstetric provider, midwife, or family physician before initiating use. Dosage adjustments may be necessary for individuals with chronic kidney disease, thalassemia trait, or history of bariatric surgery—conditions requiring individualized nutrient assessment.

Manufactured in an FDA-registered, cGMP-compliant facility in Burlington, Wisconsin. Expiration date printed on bottle: 24 months from manufacture. Store at room temperature (15–30°C); do not refrigerate. Keep out of reach of children—iron-containing supplements are a leading cause of pediatric poisoning (AAP Council on Injury, Violence, and Poison Prevention, 2023).

NutriLife Sciences’ Quality Assurance Division conducts quarterly stability testing per ICH Q1 guidelines. Batch-specific Certificates of Analysis—including heavy metals, microbiological limits, and assay results—are publicly accessible at nutrilifesciences.com/rohaan-coa using the 12-digit lot number on each bottle.

Peer-reviewed references cited in this article include: ROH-301 primary outcomes (AJOG, 2023;228:1042–1051); folate pharmacokinetics (AJCN, 2023;117:942–953); iron bioavailability (J Nutr, 2022;152:1127–1135); and cost-effectiveness modeling (JMCP, 2023;29:782–791). All data reflect publicly available, non-proprietary findings.